The Niche Episode 017 – Covance, IQVIA, ThermoFisher, Convalescent Plasma, Remdesivir

This week, siteless with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved.

Sponsors

https://www.thescopemethod.com

 

Story References

https://www.businesswire.com/news/home/20201020005645/en/LabCorp-Transforms-the-Clinical-Trial-Experience-And-Streamlines-the-Drug-Development-Process

https://www.businesswire.com/news/home/20201020005345/en/IQVIA-Reports-Third-Quarter-2020-Results-Raises-Full-Year-2020-Guidance-and-Provides-2021-Outlook

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-reports-third-quarter-2020-results-301156312.html

https://www.bmj.com/content/371/bmj.m3939

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
 

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

THIS CONTENT IS FOR

Registered Users

Please login or register to continue.